European Pharmaceutical Review

DECEMBER 14, 2023

Between 1999 and 2001, it supported 17 percent of withdrawals, between 2002 and 2011, it supported 26 percent of withdrawals and by 2012 to 2016, 80 percent of withdrawals were supported by observational studies (cohort, case-control, or other epidemiologic design). Meta-analyses contributed least frequently (31.4 2018; 8(1). EMA/95098/2010.

Safety 108

Safety Medicine Competition Networking 108

PM360

JULY 13, 2023

Our clinical data is encouraging and supports potential registrational paths based upon its molecular design focused upon selectivity for cancer-relevant T cells and decreased side effects. What Is Your Company Currently Working On? Preliminary data are expected in 2023.

Patients 98

Patients Engineering Side effects Leads 98

European Pharmaceutical Review

SEPTEMBER 22, 2023

While new positive clinical data with anti-Abeta mAbs signal tremendous advancement and proof‑of-concept for the whole field, it is believed that the observed effects could still be improved and optimised in terms of greater clinical benefits, lower side effects and enhanced treatment convenience.

Food and Drug Administration 71

Food and Drug Administration Safety Patients Leads 71